Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 2Terminated 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Thoracic 1Lymphoid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Neoplasms 21Breast Neoplasms 19Triple Negative Breast Neoplasms 16Melanoma 15Urinary Bladder Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Hepatocellular 13Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Neoplasm Metastasis 11Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Solid Tumors 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Lymphoma 5Esophageal Neoplasms 5Stomach Neoplasms 4Lung Neoplasms 4Kidney Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Urologic Neoplasms 2Solid Tumor 2

Interventions

pembrolizumab 6Nivolumab 6Ipilimumab 4Radiotherapy 3talimogene laherparepvec 2budigalimab 2avelumab 2atezolizumab 2Everolimus 2Cyclophosphamide 2zimberelimab 1venetoclax 1vatalanib 1tremelimumab 1temsirolimus 1sapanisertib 1rovalpituzumab tesirine 1poly ICLC 1oblimersen 1lorvotuzumab mertansine 1lanreotide 1glucopyranosyl lipid-A 1fludarabine 1durvalumab 1domatinostat 1cixutumumab 1cemiplimab 1aldesleukin 1Vinorelbine 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Merkel Cell × atezolizumab × Clear all
NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡